Welcome to our dedicated page for Scorpius Holdings news (Ticker: NHWK), a resource for investors and traders seeking the latest updates and insights on Scorpius Holdings stock.
Scorpius Holdings, Inc. (Symbol: NHWK), through its subsidiary Scorpius BioManufacturing, is an integrated Contract Development and Manufacturing Organization (CDMO) committed to advancing biologic programs from the laboratory to the clinic and beyond. Based in San Antonio, Texas, Scorpius offers a broad array of services including analytical testing, process development, and manufacturing. With a focus on quality and innovation, Scorpius provides partners in the pharmaceutical and biotech industries with state-of-the-art facilities and a highly experienced team.
Recently, Scorpius announced the appointment of Joe Payne as President and COO. Payne brings over 20 years of experience in biopharma and pharmaceuticals, having held leadership roles at Tergus Pharma and Alcami Corporation. His expertise in quality and regulatory affairs will be instrumental in Scorpius's next phase of growth, emphasizing quality biomanufacturing processes.
Under the leadership of Jeff Wolf, CEO of NightHawk Biosciences, Scorpius continues to prioritize transparent collaboration and flexible manufacturing solutions to meet the needs of its clients. The company's dedication to advancing biologic innovations efficiently and safely has made it a valuable partner in the industry.
Scorpius is currently engaged in multiple projects, including two phase 2 clinical trials for its proprietary Impact™ (Immune Pan-Antigen Cytotoxic Therapy). This first-in-class, fully human immunotherapy functions as both an immune stimulator and antigen-delivery system, targeting a wide range of cancers. The ongoing trials include HS-110 for non-small cell lung cancer (NSCLC) and HS-410 for bladder cancer.
NightHawk Biosciences (NYSE American: NHWK) has reported its strategic, financial, and operational updates for the year ended December 31, 2022. The company recognized $6.4 million in revenue, primarily from product sales of ANTHIM® to the Canadian government. However, it faced a net loss of $43.4 million, resulting in a loss per share of ($1.70). NightHawk is transitioning towards biodefense and biomanufacturing, investing in facilities in San Antonio and Kansas. As of December 31, 2022, it had $44.3 million in cash and equivalents, but an audit opinion raised concerns about its ability to continue as a going concern due to recurring losses.
FAQ
What is the market cap of Scorpius Holdings (NHWK)?
What does Scorpius Holdings, Inc. do?
Who is the CEO of Scorpius Holdings, Inc.?
Where is Scorpius Holdings, Inc. located?
What services does Scorpius BioManufacturing offer?
What is Impact™ therapy?
What clinical trials is Scorpius currently conducting?
Who is Joe Payne?
What makes Scorpius BioManufacturing unique?
How can I contact Scorpius Holdings, Inc. for investor relations?
What is the stock symbol for Scorpius Holdings, Inc.?
